2026-08-16 · trading-venues

Encompass Health's CFO Trimmed His Stake as Shares Jumped After Earnings. Here's What to Know

Key Points

• Coltharp executed the sale of 18,869 shares at a weighted average price of $125.38 per share on August 10.

• The transaction reduced the executive's direct equity position by 27%, while his total beneficial ownership decreased by 7%.

• Following the sale, Coltharp retains a total interest of about 241,000 shares, as reported in the Form 4 filing, including indirect positions.

• 10 stocks we like better than Encompass Health ›

Douglas E. Coltharp, EVP and chief financial officer of Encompass Health Corporation (NYSE:EHC), sold 18,869 shares of common stock on August 10 for a total transaction value of approximately $2.4 million, according to an SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average sale price ($125.38); post-transaction value based on the August 10 market close ($125.81).

Key questions

• How does this disposal impact the executive's total equity exposure?
  While the sale involved 18,869 shares of direct ownership, it represented only a small reduction in Coltharp's total interest in the company. The majority of his equity remains held indirectly through an irrevocable trust (27,480 shares), an irrevocable trust for the benefit of children (125,631 shares), and his spouse (37,749 shares).
• What financial metrics define the company's current scale?
  As of the August 10 market close, the firm carries a market capitalization of $12.5 billion. Its financial position is supported by trailing twelve-month revenue of $6.2 billion and net income of $621.0 million, reflecting its operational scale in the medical care facilities industry.
• What is the remaining scale of the executive's interest following the transaction?
  Coltharp maintains an equity interest of 241,000 shares, valued at approximately $30.4 million based on the market close on the transaction date. This position represents 0.2% of the total outstanding shares for the Birmingham-based healthcare services provider.

Company Overview

Company Snapshot

• Encompass Health Corporation operates a diversified post-acute healthcare platform delivering inpatient rehabilitation services and home health and hospice care across the United States through both dedicated facilities and in-home settings.
• The company generates revenue through its two primary divisions: Inpatient Rehabilitation, which provides focused recovery treatment on an inpatient and outpatient basis, and Home Health and Hospice, which delivers care services directly to patients in their residences.
• Encompass Health serves patients transitioning from acute care settings, including those recovering from significant illnesses, surgeries, and injuries, with a customer base comprised of healthcare systems, insurance providers, and individual patients requiring post-acute care services.

Encompass Health Corporation is a leading operator in the post-acute healthcare sector, with a market capitalization of $12.5 billion and TTM revenues of $6.2 billion, positioning it as a significant provider of rehabilitation and home-based care services. The company's diversified business model across inpatient facilities and home health services provides revenue stability and exposure to the growing demand for post-acute care driven by an aging population and the shift toward value-based care delivery. With 42,300 employees and a strong net income margin of approximately 10% on TTM revenues, Encompass Health maintains operational scale and profitability in a fragmented market characterized by consolidation opportunities.

What this transaction means for investors

This sale came on the same day as a much larger sale from the CEO of Encompass, so Coltharp's trim looks modest by comparison, and the contrast is worth noticing. Where Mark Tarr cut about 39% of his direct stake, Coltharp sold a far smaller slice and still holds the majority of his equity indirectly, spread across family trusts and his spouse. Two executives selling in the same window can look like a pattern, but the sizes tell different stories: one a sizable reduction and the other closer to routine.
Nevertheless, neither seems to point to a problem with the business. Encompass reported earlier this month that revenue grew about 10% to $1.6 billion, raised its full-year guidance for the second time this year, and boosted its dividend and buyback authorization to $1 billion, all on rising demand for its rehabilitation hospitals. Coltharp is the one who laid out those raised targets, and the stock jumped to near a 52-week high on the results. For shareholders, the CFO's small sale into that strength is the easy part to set aside, and the more useful question is simply whether Encompass keeps hitting the numbers he just raised.

Should you buy stock in Encompass Health right now?

Before you buy stock in Encompass Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Encompass Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,381,960!*

Now, it's worth noting Stock Advisor's total average return is 981% — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of August 16, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.